Skip to content
March 28, 2024

Equity.Guru

Investment information for the new generation

Search

biotech

Feliz Navidea $29.79M Market Capitalization Navidea Biopharmaceuticals Inc. (NAVB.NYSE) announced today that it has received regulatory approval in India for its Lymphoaim, also referred to as Lymphoseek in the…
A big mover in Clarus Therapeutics (CRXT) today which saw the stock at one point up over 70%! The stock sees an average volume of 1,300,000 shares. At time…
A Genetic Link I recently started watching Netflix’s Archive 81 with my girlfriend. Although we have only watched the first episode, there is a clear focus on mental health. It…
Nice Mice   Considering the amount of junk food I have eaten in the past week, I figured now is as good a time as any to talk about…
Forget-Me-Not Whether you believe in the metaphysical or not, there’s no denying the achievements of science. In particular, biotechnology has uncovered significant advancements in the field of medicine. For context,…
Old Memories I have always been a sucker for nostalgia. When I first started writing for Equity Guru, I spent most of my time covering biotechnology companies. Whether they…
Spruce Biosciences Inc. (SPRB.Q) is a late-stage biopharmaceutical company developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical needs. The Company is credited for developing its…
Drug science is all about timing. You can either take a preexisting molecule, which has benefits for alternative indications rather than what it’s originally on shelves for, and you…
Bionano Genomics (BNGO.Q) has been keeping busy lately, and the Company’s Q2 2021 Financial Results are a testament to their efforts.   Bionano has been on my radar for…
Medexus Pharmaceuticals (MDP.TO) is a rare disease pharmaceutical company with a portfolio of innovative and high value rare disease products positioning the company for growth in the next decade…